New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% reduction in major cardiovascular events, confirming powerful heart-protective effects that appear to extend beyond weight control.
Blog
Leave a Reply